Medication adherence in schizophrenia

Francisco Javier Acosta, José Luis Hernández, José Pereira, Judit Herrera, Carlos J Rodríguez

Abstract
Non-adherence is a major problem in the treatment of schizophrenia. Its high prevalence, potentially severe consequences and associated costs make the study of this phenomenon a priority issue. In this article, basic non-adherence concepts of prevalence, consequences, evaluation methods, methodological restrictions of available studies, risk factors and intervention strategies, are reviewed. Studying non-adherence risk factors is a necessary step toward designing adequately oriented intervention strategies. An operative definition of adherence and good knowledge of its evaluation methods are essential to study this phenomenon. Unfortunately, most available studies contain methodological restrictions, especially concerning the evaluation methods, and an agreed operative definition of adherence has only very recently been reached. Knowing non-adherence risk factors, intervention strategies and available evidence on their effectiveness is essential in making treatment decisions in daily clinical practice.

INTRODUCTION
In spite of recent progress in the treatment of schizophrenia during the last decades, non-adherence continues to be a frequent phenomenon, often associated to potentially severe clinical consequences [1,2] and high costs [3-5]. Estimated non-adherence rates in schizophrenia are about 50% [6]. These findings together with the fact that non-adherence is considered to be preventable [2], make the study of this phenomenon a priority objective in psychiatry that includes both the associated risk factors and the efficacy of interventions aimed at reducing it.

Compliance is defined as “the extent to which the patient’s behavior (in terms of taking medications, following diets, or executing other lifestyle changes) coincides with medical recommendations” [7]. Adherence is defined as “the extent to which the patient’s behavior (in terms of taking medications, following diets, or executing other lifestyle changes) matches medical recommendations jointly agreed between patient and prescriber” [8]. The difference between both concepts is minimal and essentially concerns the physician’s degree of authority [9].
PREVALENCE

Estimated non-adherence rates in schizophrenia are about 50%, widely ranging from 4% (observed in a study with depot neuroleptic drugs) to 72%[8]. Factors that might account for such variability include: definition of non-adherence and criteria used to determine it, methods for evaluating non-adherence and observation period[9]. Furthermore, adherence may vary during the patient’s evolution; it is usually good after hospital discharge and tends to decrease with time[10].

In a prospective study, one-third of patients admitted to hospital after their first psychotic episode of schizophrenia were non-adherents 6 mo afterwards[11]. Another prospective 2-year study showed similar results: 33.4% of patients stopped attending follow-up visits or refused to go on with the treatment[12]. In a study including male patients with a first psychotic episode of schizophrenia, schizophreniform disorder or schizoaffective disorder, 53.6% of them abandoned the treatment during the first year[13].

CONSEQUENCES OF NON-ADHERENCE

In patients with psychopathological symptoms, antipsychotic drugs have proven effective in reducing relapse and rehospitalization rates[2]; however, non-adherence is a frequent cause of impairment[6,14], hospitalization[3,15,16], higher risk of suicide[17], longer time to remission[18], poorer prognosis[19], loss of job, dangerous behavior[20], arrest, violence, drug and alcohol consumption, psychiatric emergences, poor mental performance and low satisfaction with life[21].

The risk of psychotic relapse in patients with schizophrenia and schizoaffective disorder increases almost five times after 5 years, reaching 81.9%[22]. Furthermore, relapse episodes entail more care related costs[3-5]. The annual costs of schizophrenia amount to £400 millions in the United Kingdom and over $10 billion in the United States[25]; 40% of the costs associated to treatment of schizophrenic persons are attributed to non-adherence[22].

EVALUATING NON-ADHERENCE

Classification of evaluation methods

Evaluation methods are considered to be “direct” when they offer proof that the patient has taken their medication, i.e., detection of the drug or its metabolites in the organism (generally in serum or urine), detection of a biological marker associated with the drug (or with the placebo) and direct observation of the patient. “Indirect” methods include patient’s reports (which may be evaluated through direct questioning or through psychometric scales), tablet count, pharmacy records and the use of electronic monitoring[26].

From a different point of view, evaluation methods may be classified into “objective” e.g., tablet count, pharmacy records, electronic monitoring devices and drug detection in the organism; or “subjective”, e.g., patient’s reports during interviews or scores rated by an interviewer[27].

All the available methods have advantages and disadvantages. Detection and determinations of drug levels in serum or urine demonstrate whether the patient has taken the medication but are restricted to recent intake and influenced by inter-subject pharmacokinetic variations[28]; furthermore, with novel antidepressant and antipsychotic drugs, such tests are not adequate to determine the amount of drug the patient has taken[29]. Direct observation is difficult in the case of outpatients. Interviews can be easily conducted but their results depend on the skill of the interviewer, the way of questioning and the reliability of the patient. Tablet count is easy and cost-free but offers no information on the adherence pattern; furthermore the amount of remaining tablets can be intentionally altered by the patient. Useful pharmacy records (new periodic dispensations) need to be complete and include all prescriptions and all pharmacies the patient might access[26]. Table 1 shows the main evaluation methods.

Table 1 Adherence evaluation methods

| Direct | Indirect |
|----------------|----------------|
| Detection of the drug or drug metabolites | Objective |
| Tablet count | Table count |
| Electronic monitoring | Electronic monitoring |
| Pharmacy records | Pharmacy records |
| Subjective | Subjective |
| Psychometric scales | Psychometric scales |
| Questioning the patient | Questioning the patient |
| Questioning the relatives | Questioning the relatives |
| Clinical judgment | Clinical judgment |

Subjective impression of the psychiatrist and reports by patients or relatives

Subjective impression of non-adherence has proven unreliable in a number of recent studies, which evidenced adherence overestimation by psychiatrists[26-30], patients[27,29,30] and relatives[29,30]. Studies generally show high sensitivity for detection of adherent patients but poor ability to identify non-adherents[26,30,31].

Psychometric scales

A number of psychometric scales were developed, aimed at assessing non-adherence by psychotic or specifically by schizophrenic patients. Some of them were validated for other populations of psychiatric patients or for patients with somatic disorders. Some scales were designed to evaluate non-adherence itself; others were focused on related aspects such as the attitude toward medication. Both scale types are complementary[32].

Available evaluation scales are used to assess different areas. Thus, the Drug Attitude Inventory (DAI)[32] is used to evaluate the patient’s attitude toward medication; the Brief Evaluation of Medication Influences and Beliefs (BEMIB)[33] and the Rating of Medication...
Non-adherence is a complex phenomenon, with a wide variety of patterns. From the prescribed medication, the patient might either take lower or higher doses, follow a schedule other than prescribed, completely abandon the treatment, or refuse attending regular visits or being admitted to hospital. Furthermore, the pattern may change in different phases of the disease.

A major problem emerging in related literature published until recent years involves disagreement in the definition of non-adherence and the criteria for considering it clinically relevant. Fortunately, an international consensus document was recently published on adherence to treatment by patients with serious and persistent mental disorders. Current criteria for defining non-adherence are: less than 80% of prescribed medication taken or gaps in medication of at least 7 days.

### Evaluation method

A major difficulty and restriction of available studies on adherence is the lack of validated evaluation methods. Most studies are based on indirect and subjective measurements such as information reported by patients or their relatives, or review of patients’ clinical records. Only in a few studies the reference standard method was used, namely electronic monitoring with the MEMS device. Additionally, many studies contain methodological deficiencies such as lack of a control group, poor description of the studied sample or unreliable criteria for establishing a definition of adherence.

### Risk factors

#### Sociodemographic factors

Non-adherence was reported to be more frequent in men than in women, although not in all of the relevant studies. Regarding patient’s age, younger patients show higher non-adherence rates than older ones. At the beginning of the disease, patients may distrust the diagnosis and the need for treatment, and show poorer tolerance to adverse effects. However, older patients may fail to adhere to treatments because of cognitive deficit, including working-memory loss and impaired executive performance, furthermore, they are often prescribed multiple treatments. Marital status was not found to be a risk factor. Some studies include financial difficulties and low education level among the risk factors. Thus, even when every patient should be individually evaluated, a highest-risk profile may be generally defined as corresponding to a male, young patient with low socioeconomic status.

#### General clinical factors

Although drug and alcohol consumption was suggested to be a major risk factor for non-adherence, such an association was not found in recent studies based on the use of MEMS. Association between adherence and length of illness was also not found in the later two studies; however, in other studies an association between higher non-adherence and...
longer length of illness was reported\textsuperscript{[39]}. Previous non-adherence was consistently found to be a risk factor for subsequent non-adherence\textsuperscript{[30,42,52]}. 

Psychopathological symptoms: Most studies based on subjective methods\textsuperscript{[6]} - psychiatrist's clinical impression\textsuperscript{[53]} and a recent expert consensus\textsuperscript{[42]} indicate that impaired insight is a risk factor for non-adherence. Such an association was also found in studies using the MEMS device\textsuperscript{[36,34]}, although not in all of them\textsuperscript{[28,36]}. Insight in schizophrenia is a complex and multidimensional phenomenon. Several studies have showed an association between insight and attitudes toward medication\textsuperscript{[15-57]}. Besides, an association between this latter and adherence to pharmacological treatment has been found in prospective\textsuperscript{[38,39]} and cross-sectional studies\textsuperscript{[41,60-62]}. More specifically, implicit, but not explicit, positive attitudes predicted increased insight and perceived need for treatment\textsuperscript{[62]}. Implicit attitudes are automatically activated evaluative impulses that are difficult to control and potentially outside conscious awareness\textsuperscript{[62]}. Regarding psychotic symptoms, the content of delusions may influence non-adherence. Patients with delusions of persecution or poisoning are more reluctant to take medication and those with delusion of grandeur are hardly convinced that they need it\textsuperscript{[18]}. In a prospective study with a 2-year follow-up period on patients with psychotic disorders in their first hospitalization, higher baseline intensity of delusion and suspiciousness were associated with non-adherence during subsequent follow-up\textsuperscript{[63]}. Persistent psychotic symptoms may promote non-adherence\textsuperscript{[60]}.

Findings relating negative symptoms are controversial. These symptoms have been reported to be predictive of both adherence and non-adherence\textsuperscript{[30,60-62]}. Severe negative symptoms were assumed to impair adherence through their impairing effects on patient's basic self-care abilities\textsuperscript{[49]}. Negative symptoms may interfere with the will or the ability to take medication, thus impairing adherence\textsuperscript{[49]}. Other authors claim that available data are scarce and inconclusive\textsuperscript{[42]}. The role of neurocognitive impairment in non-adherence is a complex and scarcely studied issue\textsuperscript{[4]}. Some authors reported it to be associated with non-adherence\textsuperscript{[56,64,65]}. Cognitive impairment in schizophrenia includes deficiencies in attention and memory\textsuperscript{[66]}, two processes necessary for continuing adherence\textsuperscript{[47,48]}. Neurocognitive impairment is likely to negatively influence adherence by causing oversight, comprehension difficulties or deficient organization regarding medication schedules. Furthermore, it was suggested that illness severity is not necessarily a cause of non-compliance, but it may act in a bidirectional fashion, i.e., non-compliance causing worsening of symptoms and worsening leading to lower compliance\textsuperscript{[39]}.

Psychological factors: attitudes, beliefs and other subjective aspects: The attitudes and beliefs related with health, disease and treatments are consistently associated with adherence\textsuperscript{[45]}. Attitudes vary widely, from very positive to very negative ones, and may change during the course of the disease. Patients who believe that schizophrenia is a mild disorder are more prone to non-adherence\textsuperscript{[67]}. Positive attitudes toward the treatment have been related with better adherence\textsuperscript{[70]}, while negative ones have been related with non-adherence\textsuperscript{[63,71]}. Other identified risk factors are: negative subjective response to medication\textsuperscript{[6]}; shame of taking medication\textsuperscript{[66]}; stigma\textsuperscript{[72]}, believing that the treatment is not needed and that only a minor benefit is derived from it\textsuperscript{[73]}. Subjective wellbeing is associated with better adherence\textsuperscript{[74]}.

Are there subtypes of non-adherent patients in schizophrenia? Some authors proposed a classification of non-adherent patients into two groups: intentional non-adherents including those who reject medication, and unintentional non-adherents including those with neurocognitive deficiency. Intentional non-adherence would be related with impaired insight, while unintentional non-adherence would derive from cognitive impairment\textsuperscript{[30,49]}, that results in forgetting about the medication or in deficient executive performance\textsuperscript{[70]}. In case further evidence continues to support such a classification, then different approaches should be developed for the different subgroups. Thus, therapeutic approach to intentional non-adherent patients should focus on improving insight, while approach to unintentional non-adherents should focus on improving cognitive deficiency\textsuperscript{[41,64]}. Other authors proposed that patients who reject medication should be distinguished from those who show irregular adherence\textsuperscript{[70]}.

Environment-related risk factors

Environments of poor familial and social support have been associated with non-adherence, both by patients with schizophrenia\textsuperscript{[3]} and patients with a first psychotic episode\textsuperscript{[71,75]}. Living alone is a further risk factor\textsuperscript{[12]}. While living with other people usually has protective effects, it maybe a risk factor if the involved interpersonal relationships are perceived as distressing\textsuperscript{[48]}. In this context, the fact of taking medication may become a distressing element, especially for patients who are not aware of their disease\textsuperscript{[2]}. Difficulties accessing health services are also a risk factor\textsuperscript{[22]}.

Physician-related risk factors

Having a poor relationship with the therapist\textsuperscript{[40]}, experiencing constraint during hospitalization\textsuperscript{[49,56]} and inadequate planning of the post-discharge period were reported to be risk factors for non-adherence\textsuperscript{[63]}; whereas, a good relationship with the therapist and perceived efficacy of treatment were the main factors associated with adherence\textsuperscript{[30,49]}. Both the interest shown by the physician and the psychoeducation and information provided to patients and relatives concerning the disease are important. It is recommended that the attitude toward medication of all medical team members should be consistent\textsuperscript{[48]}.
Treatment-related risk factors
Ineffectiveness of the medication against psychotic or negative symptoms may be a risk factor for non-adherence. Moreover, antipsychotic drugs exhibit delayed onset of the therapeutic effects (more delayed than adverse effects), post-withdrawal relapse events are not immediate but occur weeks or months later, and many patients in remission fail to perceive a relationship between their improved status and the effects of medication.

Adverse effects have been associated with higher non-adherence rates. The occurrence of past or present adverse effects of treatment was associated with less favorable attitudes toward antipsychotic treatments and with poorer adherence. In a prospective study including outpatients with schizophrenia, the main reported reason for non-adherence was fear of adverse effects. Clinicians should regularly evaluate possible occurrence of such effects and their relevance, when making therapy decisions.

Complexity of the medication schedule might also be a risk factor. An association between this variable and non-adherence was found in some recent MEMS studies, but not in others. Although some studies reported higher adherence with atypical antipsychotic drugs than with classical ones, such a result was not homogeneously observed in these studies. Furthermore, reported differences are rather small and certain side effects of atypical antipsychotics may also impair adherence, such as their metabolic or weight gain effects.

The administration via is potentially an important factor. Surprisingly, few studies evaluated adherence to depot or long-acting injected treatments, most of them reported high adherence rates for patients with long-term intramuscular treatment, either depot or long-acting injection, as compared to oral treatment, as well as lower relapse and re-hospitalization rates. Table 2 shows major risk factors that have been consistently associated with non-adherence in schizophrenia.

### ADHERENCE PROMOTING STRATEGIES
Up to date, short-term treatments based on simple interventions have proven efficient, although results are not consistent across different studies. However, long-term treatments require complex interventions, which have not generally proven efficient.

In a recent expert consensus document on non-adherence by patients with serious or persistent mental illness, it was recommended that social and pharmacological interventions should be the first line of action. Combined strategies are recommended, focused on specific adherence-related problems and maintained in the long term.

### Patient-related interventions
There is no universal intervention that is adequate for all non-adherent patients; thus, identifying the cause of non-adherence in every particular patient is the first step toward establishing a suitable intervention strategy aimed at reducing it.

Thus, interventions are indicated such as: improving insight in patients with poor or no awareness of their disease, reducing negative attitudes toward medication, reducing psychotic symptoms, reducing drug consumption and improving cognitive functions. Current evidence suggests that psychosocial interventions are not effective in improving adherence, when applied only to patients or when attitudinal and behavioral aspects are disregarded. Family-related interventions have proven efficient, especially long-term ones as well as those combining different strategies. Unfortunately, studies on the maintenance of their efficacy in the long term are very scarce. In a 2-year prospective study, psychosocial interventions involving patients and relatives were associated with higher adherence than control, which was maintained all through the 2 years. However, in patients with a first psychotic episode, family support was a predictor of good medication adherence only for a short period of time, since these patients required persis-
tent family support to stay on medication\textsuperscript{[1, 70]. This complex and intensive interventions with an approach based on support and problem solving (e.g., assertive community treatment) appear to improve adherence. However, the required resources often restrict applicability of such interventions\textsuperscript{[28].}

**Physician-related interventions**

The first step toward improving adherence consists in promoting physicians’ awareness that non-adherence is a problem affecting most patients\textsuperscript{[2]}. Basic recommendations include establishing a good relationship between patient and therapist, dedicating some interview time to evaluate adherence, assessing possible risk factors for non-adherence and making attempts to modify them, evaluating patient’s motivation to take medication and trying to improve it if necessary, and involving relatives whenever possible\textsuperscript{[80].}

Further recommendations\textsuperscript{[89]} include: performing routine evaluations of adherence, adapting to the patient’s needs and allowing the patient to participate in decisions concerning their treatment, promoting effective communication by using the necessary means for the patient to understand the relevant information, accepting that the patient has the right not to take medication (provided that the patient is not disabled and is sufficiently informed), periodicaly evaluating patient’s beliefs and concerns regarding the treatment and offering the necessary information about the disorder and possible therapies.

**Pharmacological treatment-related interventions**

Atypical antipsychotic drugs were expected to improve adherence, because of their better adverse effect profiles. However, no consistent findings up to date support better adherence with atypical than with classical oral antipsychotics\textsuperscript{[39]}, although methodological restrictions have been found in those studies\textsuperscript{[41]}. Recent studies based on the use of MEMS showed no differences between atypical and classical antipsychotics in terms of adherence by patients during the post-discharge period\textsuperscript{[70]} or outpatients during regular follow-up\textsuperscript{[98]}. Therefore, clinicians are recommended not to consider good tolerance as equivalent to good adherence.

When possible, pharmacological monotherapy is recommended over polytherapy because of simplicity, less adverse effects, lower risk of drug interactions and easier response evaluation\textsuperscript{[29]}. Although this issue has been scarcely studied, using treatment schedules as simple as possible is recommended, since possible cognitive deficiencies of patients with schizophrenia could impair memorization and correct execution of complex schedules\textsuperscript{[33].}

It is important to explain to the patient what they can and what they cannot achieve with the medication. Unrealistic expectancies may lead the patient to abandon the medication when such expectancies are not fulfilled\textsuperscript{[2]}. Patients should understand and agree with the specific objectives and the therapeutic strategies used to achieve them. Instructions on medications and schedules should be as simple as possible\textsuperscript{[2]}. A number of advantages have been reported for depot and long-acting injection treatments, such as: resulting in better adherence, providing the clinician with reliable adherence information\textsuperscript{[11]}, facilitating regular contact between the patient and the therapeutic team\textsuperscript{[91]}, being easier to remember than daily oral treatments\textsuperscript{[28]}, providing immediate detection of non-adherence thus facilitating early intervention\textsuperscript{[46]}, preventing antipsychotic drug substitutions due to assumed inefficiency from relapse episodes that are actually caused by non-adherence\textsuperscript{[28]}, allowing the physician to conduct interviews without questioning on medication to those patients that perceive such questioning as surveillance\textsuperscript{[90]}, and preventing the first-pass-through-liver phenomenon\textsuperscript{[91]}. Despite their advantages, such treatments are not currently used to their highest potential\textsuperscript{[829]}. There is the generalized belief that patients will be reluctant to them. However, if the physician takes time enough to explain these treatments to the patients, showing conviction on their effectiveness, most patients will agree to start with them\textsuperscript{[2]}. Authors have reported very high adherence rates, up to 96\%, in patients under depot treatment\textsuperscript{[93]}. 85\% with long-acting injected risperidone\textsuperscript{[89]} and 97\% with long-acting injection and depot\textsuperscript{[94]}.

**REFERENCES**

1. Kane JM. Compliance issues in outpatient treatment. J Clin Psychopharmacol 1985; 5: 225-278
2. Kane JM. Treatment adherence and long-term outcomes. CNS Spectr 2007; 12: 21-26
3. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161: 692-699
4. Thiéda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508-516
5. Weiden PJ, Olsson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-429
6. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892-909
7. Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sackett DL, editors. Compliance in health care. Baltimore: John Hopkins University Press, 1979: 1-7
8. Barofsky I. Compliance, adherence and the therapeutic alliance: steps in the development of self-care. Soc Sci Med 1978; 12: 369-376
9. NCCSDO. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). 2005. Available from: URL: http://www.medlearning.leeds.ac.uk/pages/documents/useful_docs/76-final-report%5B1%5D.pdf
10. Riolo SA, Weston CG. Patient Compliance. In: Tasman A, Kay J, Lieberman JA, First MB, Maj M, editors. Psychiatry. 3rd ed. Hoboken: John Wiley and Sons, 2008: 2447-2461
11. Kamali M, Kelly BD, Clarke M, Browne S, Gervin M, Kinsella A, Lane A, Larkin E, O’Callaghan E. A prospective evalu-
of adherence to medication in first episode schizophrenia. *Eur Psychiatry* 2006; 21: 29-33

12 **Linden M**, Godemann F, Gaebel W, Köpke W, Müller P, Müller-Spahn F, Pätzker A, Tegeler J. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. *Schizophr Bull* 2001; 27: 585-596

13 **Novak-Grubic V**, Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophrenomform and schizoaffective disorder. *Eur Psychiatry* 2002; 17: 148-154

14 **Robinson D**, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry* 1999; 56: 241-247

15 **Diaz E**, Levine HB, Sullivan MC, Sernyak MJ, Hawkins KA, Cramer JA, Woods SW. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. *J Psychiatry Neurosci* 2001; 26: 325-329

16 **Rittmannsberger H**, Pachinger T, Keppelmüller F, Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. *PsychiatrSORT* 2004; 55: 174-179

17 **Hawton K**, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. *Br J Psychiatry* 2005; 187: 9-20

18 **Leucht S**, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. *J Clin Psychiatry* 2006; 67 Suppl 5: 3-8

19 **Tachdjian MJ**, Scott J. The cost and consequences of inadequate treatment. In: Tachdjian MJ, Scott J, editors. Improving adherence in schizophrenia and bipolar disorders. Chichester, UK: John Wiley & Sons, 2005: 9-15

20 **Burton SC**. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. *J Psychiatr Pract* 2005; 11: 369-378

21 **Ascher-Svanum H**, Faries DE, Zhu B, Ernst FK, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. *J Clin Psychiatry* 2006; 67: 453-460

22 **Perkins DO**. Predictors of noncompliance in patients with schizophrenia. *J Clin Psychiatry* 2002; 63: 1121-1128

23 **Byerly MJ**, Nakonezny PA, Lescouffier E. Antipsychotic medication adherence in schizophrenia. *Psychiatr Clin North Am* 2007; 30: 407-452

24 **Farmer KC**. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. *Clin Ther* 1999; 21: 1074-1090; discussion 1073

25 **Sajatovic M**, Velligan DI, Weiden PJ, Valenstein MA, Ogedegbe G. Measurement of psychiatric treatment adherence. *J Psychiatr Pract* 2010; 16: 591-599

26 **Byerly M**, Fisher R, Whitley K, Holland R, Varghese F, Cardmody T, Magouirk B, Rush AJ. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. *Psychiatry Res* 2005; 133: 129-133

27 **Byerly MJ**, Thompson A, Cardmody T, Bugno R, Erwin T, Kashner M, Rush AJ. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. *Psychiatry Res* 2007; 58: 844-847

28 **Remington G**, Kwon J, Collins A, Laporte D, Mann S, Chris-tensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. *Schizophr Res* 2007; 90: 229-237

29 **Velligan DI**, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. *Psychiatry Res* 2007; 21: 107-114

30 **Velligan DI**, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL. Defining and assessing adherence to oral antipsychotics: a review of the literature. *Schizophr Bull* 2006; 32: 724-742

31 **Acosta FJ**, Bosch E, Sarmiento G, Juanes N, Caballero-Hidalgo A, Mayans T. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. *Schizophr Res* 2009; 107: 213-217

32 **Hui CL**, Chen EY, Kan C, Yip K, Law C, Chiu CP. Anti-psychotics adherence among out-patients with schizophrenia in Hong Kong. *Kao J Med* 2006; 55: 9-14

33 **Hogan TP**, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. *Psychol Med* 1983; 13: 177-183

34 **Dolder CR**, Lacro JP, Warren KA, Golshan S, Perkins DO, Jeste DV. Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. *J Clin Psychopharmacol* 2004; 24: 404-409

35 **Weiden P**, Rapkin B, Mott T, Zygymunt A, Goldman D, Horvitz-Lennon M, Frances A. Rating of medication influences (ROMI) scale in schizophrenia. *Schizophr Bull* 1994; 20: 297-310

36 **Thompson K**, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. *Schizophr Res* 2000; 42: 241-247

37 **Morisky DE**, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care* 1986; 24: 67-74

38 **Byerly MJ**, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. *Schizophr Res* 2008; 100: 69-79

39 **Nakonezny PA**, Byerly MJ. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. *Schizophr Res* 2006; 82: 107-114

40 **Robinson DG**, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. *Schizophr Res* 2002; 57: 209-219

41 **Hui CL**, Chen EY, Kan CS, Yip KC, Law CW, Chiu CP. Detection of non-adherent behaviour in early psychosis. *Aust N Z J Psychiatry* 2006; 40: 446-451

42 **Kikkert MJ**, Barbui C, Koeter MW, David AS, Leese M, Tansella M, Gieler A, Puschner B, Scheur AH. Assessment of medication adherence in patients with schizophrenia: the Achilles heel of adherence research. *J Nerv Ment Dis* 2008; 196: 274-281

43 **Velligan DI**, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. *J Clin Psychiatry* 2009; 70 Suppl 4: 1-46; quiz 47-48

44 **Velligan DI**, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. *J Psychiatr Pract* 2010; 16: 306-324

45 **Velligan DI**, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. *J Psychiatr Pract* 2010; 16: 34-45

46 **Awad AG**. Antipsychotic medications: compliance and attitudes towards treatment. *Carr Opin Psychiat* 2004; 17: 75-80

47 **Ascher-Svanum H**, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. *J Clin Psychiatry* 2006; 67: 1114-1123

48 **Oehl MA**, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. *Acta Psychiatr Scand Suppl* 2000; 407: 83-86

49 **Fleischhacker WW**, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. *J Psychiatr Pract*
Acosta FJ et al. Medication adherence in schizophrenia

2003; 64 Suppl 16: 10-13

Rodriguez A. El paciente esquizofrénico y su enfermedad como factores determinantes en el cumplimiento terapéutico. In: Cañas F, Roca M, editors. Adherencia terapéutica en la esquizofrenia y otros trastornos psiquiátricos. Barcelona: Ars Médica, 2007: 109-117

Insel K. Morrow D, Brewer B, Figueredo A. Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci 2006; 61: P102-P107

Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C, Di-rani R, Menzin J. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv 2010; 61: 1239-1247

Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010; 176: 109-113

Olsson M, Marcus SC, Wilk J, West JC. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr Ser 2006; 57: 205-211

Byerly MJ, Fisher R, Carmody T, Rush AJ. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005; 66: 997-1001

Freudereich C, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004; 65: 1572-1576

Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005; 62: 717-724

Rocca P, Crivelli B, Marino F, Mongini T, Portaleone F, Boggetto F. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Compr Psychiatry 2008; 49: 170-176

O’Donnell C, Donohoe G, Sharkley L, Owens N, Migone M, Harries R, Kinsella A, Larkin C, O’Callaghan E. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 2003; 327: 834

Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 2009; 35: 336-346

Holzinger A, Löffler W, Muller P, Priebe S, Angermeyer MC. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia. J Nerv Ment Dis 2002; 190: 597-603

Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, Fleischhacker WW. Compliance in schizophrenia: psychopathology, side effects, and patients’ attitudes toward the illness and medication. J Clin Psychiatry 2004; 65: 1211-1218

RüsCH N, Todd AR, Bodenhausen GV, Weiden PJ, Corrigan PW. Implicit versus explicit attitudes toward psychiatric medication: Implications for insight and treatment adherence. Schizophr Res 2009; 112: 119-122

Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, van Os J. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 2000; 102: 203-210

Cuffel BJ, Alford J, Fischer EP, Owen RR. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis 1996; 184: 653-659

Spielmenn A, Schulz M, Behrens J, Driessen M, Rahn E, Beblo T. [Adherence and cognitive performance in schizophrenia]. Fortschr Neurol Psychiatr 2011; 79: 73-82

Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychi atr Clin North Am 2003; 26: 25-40

Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003; 64: 1308-1315

Jeste SD, Patterson TL, Palmer BW, Dolder CR, Goldman S, Jeste DV. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res 2003; 63: 49-58

Rosa MA, Marcolin MA, Ellis H. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rev Bras Psiquiat 2005; 27: 178-184

Meier J, Becker T, Patel A, Robson D, Schene A, Kikker M, Barbu C, Burti L, Puschner B. Effect of medication-related factors on adherence in people with schizophrenia: a European multi-centre study. Epidemiol Psychiatr Soc 2010; 19: 251-259

Quach PL, Mors O, Christensen TO, Krarup G, Jørgensen P, Bertelsen M, Jepjesen P, Petersen L, Thorup A, Nordenfelt M. Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Interv Psychiatry 2009; 3: 66-74

Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry 2004; 65: 211-216

Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006; 83: 53-63

Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, Schimmelmann BG, Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007; 68: 75-80

Rabinovitch M, Béchard-Evans L, Schmitz N, Joober R, Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatry 2009; 54: 28-35

Löffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients’ subjective reasons for compliance and non-compliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105-112

Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, Golka D, Naber D. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004; 19: 415-422

Yamada K, Watanabe K, Nemoto N, Fujita H, Chikaraisi C, Yamachi K, Yagi G, Asai M, Kanba S. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res 2006; 141: 61-69

Díaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65: 354-360

Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010; 26: 501-509

Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127: 83-92

Haynes RB, Ackloe E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 2: CD000011

Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of
recent literature. J Clin Psychopharmacol 2003; 23: 389-399
84 Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia—a review of the past decade. Eur Psychiatry 2012; 27: 9-18
85 National Institute for Health and Clinical Excellence (NICE). Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical Guideline Clinical guidelines, CG76. London, UK: NICE, 2009
86 Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 2007; 68 Suppl 14: 14-19
87 Zygmunt A, Olsson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159: 1653-1664
88 Nosé M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003; 183: 197-206
89 Pitschel-Walz G, Báuml J, Bender W, Engel RR, Wagner M, Kissling W. Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. J Clin Psychiatry 2006; 67: 443-452
90 Julius RJ, Novitsky MA, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009; 15: 34-44
91 Kane JM. Review of treatments that can ameliorate non-adherence in patients with schizophrenia. J Clin Psychiatry 2006; 67 Suppl 5: 9-14
92 Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001; 62: 545-551
93 Heyscue BE, Levin GM, Merrick JP. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998; 49: 1232-1234

S- Editor Song XX L- Editor A E- Editor Zheng XM